Observational studyBMC cardiovascular disorders2016

Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.

Chao-Feng Lin et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 24,975 people · 2016

Not counted

Lowered adverse events & safety

−24%−36% to −10%

Bigger than 6 in 10 for adverse events & safety

As reported

OR 0.76, 95% CI 0.64–0.90

Range includes no effect

No clear effect on adverse events & safety

+14%−15% to +52%

Bigger than 4 in 10 for adverse events & safety

As reported

OR 1.14, 95% CI 0.85–1.52

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower adverse events & safety

−15%−23% to −5%

Bigger than 4 in 10 for adverse events & safety

As reported

OR 0.85, 95% CI 0.77–0.95

Correlation, not cause

Went with fewer cardiovascular events

−24%−36% to −10%

Bigger than 6 in 10 for cardiovascular events

As reported

OR 0.76, 95% CI 0.64–0.90

Correlation, not cause

Went with lower adverse events & safety

−25%−34% to −16%

Bigger than 6 in 10 for adverse events & safety

As reported

OR 0.75, 95% CI 0.66–0.84

+1 more in the walkthrough ↓

Six numbers in the abstract

the abstract, start to end

… MI patients (adjusted odds ratio [aOR] = 0.85, 95% confidence interval [CI] = …

… unexposed to statin pretreatment (aOR = 0.76, 95% CI = 0.64-0.90, P = …

… effect of a DDD90 of 0.5-1.0 (aOR 0.75, 95 % CI 0.66-0.84, P < 0.001) …

… risk of pneumonia hospitalization (aOR 0.76, 95 % CI 0.64-0.90, P = 0.001).

… we controlled for all risk factors (aOR 0.85, 95 % CI 0.77-0.95, P = 0.004) …

… to atorvastatin (fluvastatin: aOR 1.14, 95 % CI 0.85-1.52, P = 0.390; …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

OR 0.850.77–0.95

Cardiovascular events

OR 0.760.64–0.90

Adverse events & safety

OR 0.750.66–0.84

Adverse events & safety

OR 0.760.64–0.90

Adverse events & safety

OR 0.850.77–0.95

Adverse events & safety

OR 1.140.85–1.52

StatinsCardiovascular eventsAdverse events & safety

1 / 3

10 papers cite it

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

this papercites it

Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.

What the trial testedas reported · 24,975 people · 2016

Lowered adverse events & safety

No clear effect on adverse events & safety

What moved togetherboth groups pooled, not the treatment’s effect

Went with lower adverse events & safety

Went with fewer cardiovascular events

Went with lower adverse events & safety

Six numbers in the abstract

Where each one falls

Where it lands on the map

10 papers cite it